GlassScriptPhysician profile
Laura Lea Aul
NPI 1801126461
$638.79
in general payments reported to CMS, 2019-2025
14 companies · $243 in 2025
The $243 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $178 · 2023: $172 · 2024: $44.82 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $460.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $136.84 | 2021 | |
| Pfizer INC. | $65.97 | 2023-2025 | |
| Exact Sciences Corporation | $64.37 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Abbvie INC. | $56.33 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $56.10 | 2021-2025 | Farxiga |
| Amgen INC. | $41.87 | 2024-2025 | Otezla, Repatha, Repatha |
| Astellas Pharma US INC | $39.97 | 2025 | Veozah |
| Novo Nordisk INC | $37.98 | 2024-2025 | Ozempic |
| Abbott Laboratories | $35.39 | 2023-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $31.43 | 2023 | Mounjaro |
| Greenwich Biosciences, INC. | $24.27 | 2021 | |
| Idorsia Pharmaceuticals US INC | $17.51 | 2023 | Quviviq |
| Esperion Therapeutics, INC. | $16.65 | 2023 | Nexletol |
| Sanofi Pasteur INC. | $14.11 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Aul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.